Related Experiment Videos
Proliferative cell nuclear antigen in postradiotherapy prostate biopsies
J Crook1, S Robertson, B Esche
1Department of Radiation Oncology, Ottawa Regional Cancer Center, Canada.
International Journal of Radiation Oncology, Biology, Physics
|September 30, 1994
Summary
Proliferative cell nuclear antigen (PCNA) staining helps differentiate active from inactive residual prostate cancer after radiation. Negative PCNA in biopsies indicates tumor resolution, while positive PCNA correlates with local failure.
Area of Science:
- Oncology
- Pathology
- Radiotherapy
Background:
- Distinguishing biologically active residual prostate cancer post-radiotherapy is crucial for patient management.
- Traditional biopsy methods may not reliably differentiate between treatment effects and persistent disease.
Purpose of the Study:
- To evaluate the utility of proliferative cell nuclear antigen (PCNA) staining in postradiotherapy prostate biopsies.
- To correlate PCNA staining results with clinical outcomes and tumor activity.
Main Methods:
- Systematic transrectal ultrasound-guided biopsies were performed on 162 patients post-radiotherapy for prostate cancer.
- Biopsies were stained for prostate-specific antigen, prostatic acid phosphatase, and PCNA.
- Keratin 903 was used to identify radiation atypia versus residual cancer.
Main Results:
- Negative PCNA staining in initially positive biopsies predicted tumor resolution in 83-97% of cases.
- Positive PCNA staining correlated with local failure (49-79%) but could disappear in early biopsies.
- One patient with initially negative PCNA staining experienced local failure.
Conclusions:
- PCNA staining is a valuable tool for assessing residual prostate cancer activity after radiotherapy.
- Negative PCNA is a strong indicator of successful treatment and tumor resolution.
- Positive PCNA suggests a higher risk of local recurrence, though its persistence needs monitoring.